Bio-Rad Laboratories, Inc. (BIO) PE Ratio: 48.96
Is Bio-Rad Laboratories, Inc.’s P/E ratio high or low?
Bio-Rad Laboratories, Inc.'s P/E ratio of 48.96 is 650% above its 5-year average of 6.53, near the high end of its 5-year range (1.55–52.43).
The P/E ratio for Bio-Rad Laboratories, Inc. (BIO) is 48.96 as of Tuesday, June 9, 2026. It is above its 12-month average by 139.23% (20.47).
PE Ratio (48.96) = Close Price ($297.17) / Diluted TTM EPS ($6.07)
BIO PE Ratio Chart
BIO Average PE Ratio Chart
BIO Current vs Average PE Ratio Chart
BIO PE Ratio Metrics
PE RATIO
48.96
PE RATIO AVG TTM
20.47
PE RATIO AVG 3Y
8.38
PE RATIO AVG 5Y
6.53
PE RATIO AVG 10Y
50.36
PE RATIO AVG 15Y
43.91
PE RATIO AVG 20Y
38.40
CURRENT VS TTM AVG
+139.23%
CURRENT VS 3Y AVG
+484.56%
CURRENT VS 5Y AVG
+649.66%
CURRENT VS 10Y AVG
-2.78%
CURRENT VS 15Y AVG
+11.51%
CURRENT VS 20Y AVG
+27.49%
BIO Competitors' PE Ratio
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | — | 48.96 | 20.47 | 8.38 | 6.53 |
| Charles River Laboratories International, Inc. (CRL) | $9.14B | N/A | 1153.70 | 496.08 | 311.08 |
| Hims & Hers Health, Inc. (HIMS) | $6.46B | N/A | 59.25 | 86.72 | 86.72 |
| Align Technology, Inc. (ALGN) | $12.76B | 29.88 | 29.31 | 42.93 | 47.88 |
| Hologic, Inc. (HOLX) | $16.97B | 31.67 | 28.12 | 30.08 | 22.83 |
| Moderna, Inc. (MRNA) | $18.94B | N/A | 13.31 | 22.55 | 25.04 |
| BioNTech SE (BNTX) | $21.87B | N/A | 237.28 | 176.83 | 109.05 |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 27.23 | 32.01 | 32.81 | 36.46 |
| Waters Corporation (WAT) | $24.19B | 47.16 | 31.85 | 30.89 | 30.42 |
| Veeva Systems Inc. (VEEV) | $27.37B | 29.89 | 47.22 | 54.69 | 66.93 |
P/E vs. its own history
At 49.0, P/E is richer than usual — richer than 89% of its 20-year range.
20-year low
1.6
median
18.8
20-year high
532.6
P/E Comparison
Trailing P/E
49.0
Forward P/E
29.8
Forward P/E Calculation
View All Analyst EstimatesForward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$297.17
Forward EPS (Est.)
$9.96
Forward P/E
29.82
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
Bio-Rad Laboratories, Inc. PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. PE Ratio FAQ
- What is the P/E ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The P/E ratio for BIO stock is 48.96.
- Is Bio-Rad Laboratories, Inc.'s P/E ratio high or low?
- Bio-Rad Laboratories, Inc.'s P/E ratio of 48.96 is 650% above its 5-year average of 6.53, near the high end of its 5-year range (1.55–52.43).
- What is the TTM average P/E ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average P/E ratio for BIO stock is 20.47.
- What is the 3Y average P/E ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average P/E ratio for BIO stock is 8.38.
- What is the 5Y average P/E ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average P/E ratio for BIO stock is 6.53.
- What is the 10Y average P/E ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average P/E ratio for BIO stock is 50.36.
- What is the 15Y average P/E ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average P/E ratio for BIO stock is 43.91.
- What is the 20Y average P/E ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average P/E ratio for BIO stock is 38.40.
Bio-Rad Laboratories, Inc. PE Ratio History
| DATE | PE RATIO |
|---|---|
| 2026-06-03 | 50.22 |
| 2026-06-02 | 50.43 |
| 2026-06-01 | 50.32 |
| 2026-05-29 | 51.48 |
| 2026-05-28 | 52.43 |
| 2026-05-27 | 50.29 |
| 2026-05-26 | 48.91 |
| 2026-05-22 | 47.40 |
| 2026-05-21 | 47.24 |
| 2026-05-20 | 47.42 |
| 2026-05-19 | 46.30 |
| 2026-05-18 | 46.43 |
| 2026-05-15 | 40.78 |
| 2026-05-14 | 40.57 |
| 2026-05-13 | 40.12 |
| 2026-05-12 | 39.82 |
| 2026-05-11 | 40.16 |
| 2026-05-08 | 41.90 |
| 2026-05-07 | 42.39 |
| 2026-05-06 | 42.67 |
| 2026-05-05 | 42.36 |
| 2026-05-04 | 42.48 |
| 2026-05-01 | 42.27 |
| 2026-04-30 | 46.15 |
| 2026-04-29 | 9.86 |
| 2026-04-28 | 10.01 |
| 2026-04-27 | 10.29 |
| 2026-04-24 | 10.31 |
| 2026-04-23 | 10.08 |
| 2026-04-22 | 10.78 |
| 2026-04-21 | 10.95 |
| 2026-04-20 | 10.87 |
| 2026-04-17 | 10.71 |
| 2026-04-16 | 10.43 |
| 2026-04-15 | 10.60 |
| 2026-04-14 | 10.47 |
| 2026-04-13 | 10.32 |
| 2026-04-10 | 10.01 |
| 2026-04-09 | 9.94 |
| 2026-04-08 | 10.07 |
| 2026-04-07 | 9.96 |
| 2026-04-06 | 9.99 |
| 2026-04-02 | 10.03 |
| 2026-04-01 | 9.97 |
| 2026-03-31 | 9.99 |
| 2026-03-30 | 9.69 |
| 2026-03-27 | 9.51 |
| 2026-03-26 | 9.91 |
| 2026-03-25 | 9.80 |
| 2026-03-24 | 9.75 |
| 2026-03-23 | 9.49 |
| 2026-03-20 | 9.48 |
| 2026-03-19 | 9.49 |
| 2026-03-18 | 9.60 |
| 2026-03-17 | 9.66 |
| 2026-03-16 | 9.36 |
| 2026-03-13 | 9.42 |
| 2026-03-12 | 9.38 |
| 2026-03-11 | 9.67 |
| 2026-03-10 | 9.60 |
| 2026-03-09 | 9.73 |
| 2026-03-06 | 9.67 |
| 2026-03-05 | 10.00 |
| 2026-03-04 | 10.20 |
| 2026-03-03 | 10.04 |
| 2026-03-02 | 10.02 |
| 2026-02-27 | 9.98 |
| 2026-02-26 | 9.86 |
| 2026-02-25 | 9.66 |
| 2026-02-24 | 9.63 |
| 2026-02-23 | 9.61 |
| 2026-02-20 | 9.72 |
| 2026-02-19 | 9.74 |
| 2026-02-18 | 9.70 |
| 2026-02-17 | 9.49 |
| 2026-02-13 | 9.19 |
| 2026-02-12 | 10.48 |
| 2026-02-11 | 25.04 |
| 2026-02-10 | 25.57 |
| 2026-02-09 | 25.14 |
| 2026-02-06 | 25.70 |
| 2026-02-05 | 25.54 |
| 2026-02-04 | 26.08 |
| 2026-02-03 | 25.49 |
| 2026-02-02 | 25.36 |
| 2026-01-30 | 25.04 |
| 2026-01-29 | 25.14 |
| 2026-01-28 | 25.56 |
| 2026-01-27 | 25.38 |
| 2026-01-26 | 25.51 |
| 2026-01-23 | 25.28 |
| 2026-01-22 | 26.02 |
| 2026-01-21 | 26.56 |
| 2026-01-20 | 26.66 |
| 2026-01-16 | 26.73 |
| 2026-01-15 | 27.46 |
| 2026-01-14 | 27.13 |
| 2026-01-13 | 27.47 |
| 2026-01-12 | 27.54 |
| 2026-01-09 | 27.61 |
| 2026-01-08 | 27.20 |
| 2026-01-07 | 27.63 |
| 2026-01-06 | 27.75 |
| 2026-01-05 | 27.48 |
| 2026-01-02 | 26.02 |
| 2025-12-31 | 25.83 |
| 2025-12-30 | 25.96 |
| 2025-12-29 | 25.89 |
| 2025-12-26 | 25.91 |
| 2025-12-24 | 25.72 |
| 2025-12-23 | 25.66 |
| 2025-12-22 | 25.99 |
| 2025-12-19 | 25.71 |
| 2025-12-18 | 25.56 |
| 2025-12-17 | 25.68 |
| 2025-12-16 | 25.75 |
| 2025-12-15 | 26.25 |
| 2025-12-12 | 26.27 |
| 2025-12-11 | 26.77 |
| 2025-12-10 | 26.85 |
| 2025-12-09 | 26.26 |
| 2025-12-08 | 26.30 |
| 2025-12-05 | 27.08 |
| 2025-12-04 | 27.29 |
| 2025-12-03 | 27.31 |
| 2025-12-02 | 27.16 |
| 2025-12-01 | 27.41 |
| 2025-11-28 | 27.69 |
| 2025-11-26 | 27.88 |
| 2025-11-25 | 28.32 |
| 2025-11-24 | 27.49 |
| 2025-11-21 | 27.00 |
| 2025-11-20 | 25.88 |
| 2025-11-19 | 25.98 |
| 2025-11-18 | 26.24 |
| 2025-11-17 | 25.92 |
| 2025-11-14 | 26.70 |
| 2025-11-13 | 27.02 |
| 2025-11-12 | 27.90 |
| 2025-11-11 | 26.71 |
| 2025-11-10 | 26.20 |
| 2025-11-07 | 26.05 |
| 2025-11-06 | 26.13 |
| 2025-11-05 | 26.43 |
| 2025-11-04 | 26.51 |
| 2025-11-03 | 26.55 |
| 2025-10-31 | 27.24 |
| 2025-10-30 | 25.97 |
| 2025-10-29 | 27.24 |
| 2025-10-28 | 28.17 |
| 2025-10-27 | 28.65 |
| 2025-10-24 | 28.96 |
| 2025-10-23 | 28.87 |
| 2025-10-22 | 28.47 |
| 2025-10-21 | 28.24 |
| 2025-10-20 | 27.44 |
| 2025-10-17 | 26.43 |
| 2025-10-16 | 26.63 |
| 2025-10-15 | 26.07 |
| 2025-10-14 | 26.01 |
| 2025-10-13 | 25.89 |
| 2025-10-10 | 25.38 |
| 2025-10-09 | 25.63 |
| 2025-10-08 | 25.82 |
| 2025-10-07 | 25.28 |
| 2025-10-06 | 26.36 |
| 2025-10-03 | 26.04 |
| 2025-10-02 | 25.08 |
| 2025-10-01 | 25.40 |
| 2025-09-30 | 23.90 |
| 2025-09-29 | 23.03 |
| 2025-09-26 | 23.13 |
| 2025-09-25 | 23.05 |
| 2025-09-24 | 23.58 |
| 2025-09-23 | 24.05 |
| 2025-09-22 | 24.16 |
| 2025-09-19 | 24.22 |
| 2025-09-18 | 24.42 |
| 2025-09-17 | 23.90 |
| 2025-09-16 | 24.06 |
| 2025-09-15 | 23.89 |
| 2025-09-12 | 23.90 |
| 2025-09-11 | 24.37 |
| 2025-09-10 | 23.61 |
| 2025-09-09 | 24.38 |
| 2025-09-08 | 24.76 |
| 2025-09-05 | 25.19 |
| 2025-09-04 | 24.67 |
| 2025-09-03 | 24.56 |
| 2025-09-02 | 24.78 |
| 2025-08-29 | 25.39 |
| 2025-08-28 | 25.04 |
| 2025-08-27 | 24.97 |
| 2025-08-26 | 25.29 |
| 2025-08-25 | 25.35 |
| 2025-08-22 | 25.90 |
| 2025-08-21 | 24.30 |
| 2025-08-20 | 24.57 |
| 2025-08-19 | 24.58 |
| 2025-08-18 | 24.27 |
| 2025-08-15 | 24.35 |
| 2025-08-14 | 24.49 |
| 2025-08-13 | 24.48 |
| 2025-08-12 | 23.42 |
| 2025-08-11 | 22.55 |
| 2025-08-08 | 22.52 |
| 2025-08-07 | 22.61 |
| 2025-08-06 | 22.53 |
| 2025-08-05 | 23.20 |
| 2025-08-04 | 23.60 |
| 2025-08-01 | 24.26 |
| 2025-07-31 | 20.63 |
| 2025-07-30 | 1.79 |
| 2025-07-29 | 1.80 |
| 2025-07-28 | 1.81 |
| 2025-07-25 | 1.89 |
| 2025-07-24 | 1.87 |
| 2025-07-23 | 1.84 |
| 2025-07-22 | 1.75 |
| 2025-07-21 | 1.74 |
| 2025-07-18 | 1.76 |
| 2025-07-17 | 1.78 |
| 2025-07-16 | 1.77 |
| 2025-07-15 | 1.77 |
| 2025-07-14 | 1.79 |
| 2025-07-11 | 1.83 |
| 2025-07-10 | 1.86 |
| 2025-07-09 | 1.81 |
| 2025-07-08 | 1.79 |
| 2025-07-07 | 1.76 |
| 2025-07-03 | 1.80 |
| 2025-07-02 | 1.79 |
| 2025-07-01 | 1.77 |
| 2025-06-30 | 1.72 |
| 2025-06-27 | 1.74 |
| 2025-06-26 | 1.74 |
| 2025-06-25 | 1.72 |
| 2025-06-24 | 1.70 |
| 2025-06-23 | 1.68 |
| 2025-06-20 | 1.69 |
| 2025-06-18 | 1.66 |
| 2025-06-17 | 1.65 |
| 2025-06-16 | 1.65 |
| 2025-06-13 | 1.62 |
| 2025-06-12 | 1.66 |
| 2025-06-11 | 1.64 |
| 2025-06-10 | 1.65 |
| 2025-06-09 | 1.61 |
| 2025-06-06 | 1.57 |
| 2025-06-05 | 1.57 |
| 2025-06-04 | 1.59 |
| 2025-06-03 | 1.57 |
| 2025-06-02 | 1.55 |
| 2025-05-30 | 1.62 |
| 2025-05-29 | 1.62 |
| 2025-05-28 | 1.64 |
| 2025-05-27 | 1.64 |
| 2025-05-23 | 1.60 |
| 2025-05-22 | 1.62 |
| 2025-05-21 | 1.63 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz